340B Advocacy Alliance Bulletin

Following the recent district court decision to remand to the Department of Health and Human Services the question of how to repay 340B hospitals for funds unlawfully withheld for five years,
Drugmakers that participate in the 340B drug pricing program do not have to provide discounted 340B drugs to an unlimited number of contract pharmacies, the U.S. Court of Appeals for the 3rd Circuit ruled today in Sanofi-Aventis U.S. v. HHS et al. Cases raising similar legal questions are pending…
AHA 340B Hospital Members Urged to Submit Comments on HRSA’s Proposed Rule on the 340B Administrative Dispute Resolution Process, Model Comment Letter Available
The U.S. District Court for the District of Columbia today decided to allow the Department of Health and Human Services to propose an appropriate remedy for its past underpayments to hospitals participating in the 340B Drug Pricing Program.
Digital ad campaign from AHA, others spotlights the importance and value of the 340B program The AHA, along with six other national hospital groups, is running a new digital ad campaign promoting to policymakers and influencers the benefits of the 340B program to patients and communities
The AHA today released a new report showing how the unlawful actions of drug companies to limit 340B pricing with community and specialty pharmacies are having an adverse impact on access to care for patients and communities across the country.
The AHA has issued a Special Bulletin with details on provisions of the Centers for Medicare & Medicaid Services’ outpatient prospective payment system final rule for calendar year 2023, which includes updates to policies for the 340B Drug Pricing Program.
It’s in everyone’s best interest to keep the 340B program strong, wrote AHA President and CEO Rick Pollack in the Congress Blog at The Hill, published Oct. 10.
After court ruling for AHA in 340B case, HHS says it will start adjusting payment rates for certain 340B hospitals within approximately two weeks